Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stacy Lindborg

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Clinical Trials (London, England)|December 20, 2012
Panel discussion 2Gordon Lan, Stacy Lindborg, James Neaton
Pharmaceutical Statistics|June 1, 2017
Covariate-adjusted borrowing of historical control data in randomized clinical trialsBaoguang Han, Jia Zhan, Z John Zhong, et al.
Journal of Psychiatric Research|September 23, 2008
Bayesian adaptive non-inferiority with safety assessment: retrospective case study to highlight potential benefits and limitations of the approachMelissa Spann, Stacy Lindborg, John Seaman, et al.
The American Journal of Psychiatry|May 3, 2005
Evidence for onset of antipsychotic effects within the first 24 hours of treatmentShitij Kapur, Tamara Arenovich, Ofer Agid, et al.
Multiple Sclerosis and Related Disorders|December 14, 2019
Impact of informative censoring on the treatment effect estimate of disability worsening in multiple sclerosis clinical trialsKatherine Riester, Ludwig Kappos, Krzysztof Selmaj, et al.
Journal of Biopharmaceutical Statistics|March 16, 2012
A portfolio-based approach to optimize proof-of-concept clinical trialsCraig Mallinckrodt, Geert Molenberghs, Charles Persinger, et al.
Stem Cell Research & Therapy|January 20, 2021
MSC-NTF (NurOwn®) exosomes: a novel therapeutic modality in the mouse LPS-induced ARDS modelHaggai Kaspi, Jonathan Semo, Nathalie Abramov, et al.
Pharmaceutical Statistics|August 6, 2013
Use of historical control data for assessing treatment effects in clinical trialsKert Viele, Scott Berry, Beat Neuenschwander, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 16, 2022
Evaluation of neurotrophic factor secreting mesenchymal stem cells in progressive multiple sclerosisJeffrey A Cohen, Fred D Lublin, Christoper Lock, et al.
The American Journal of Psychiatry|May 2, 2006
Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosisThomas H McGlashan, Robert B Zipursky, Diana Perkins, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Clinical Trials (London, England)|December 20, 2012
Panel discussion 2Gordon Lan, Stacy Lindborg, James Neaton
Pharmaceutical Statistics|June 1, 2017
Covariate-adjusted borrowing of historical control data in randomized clinical trialsBaoguang Han, Jia Zhan, Z John Zhong, et al.
Journal of Psychiatric Research|September 23, 2008
Bayesian adaptive non-inferiority with safety assessment: retrospective case study to highlight potential benefits and limitations of the approachMelissa Spann, Stacy Lindborg, John Seaman, et al.
The American Journal of Psychiatry|May 3, 2005
Evidence for onset of antipsychotic effects within the first 24 hours of treatmentShitij Kapur, Tamara Arenovich, Ofer Agid, et al.
Multiple Sclerosis and Related Disorders|December 14, 2019
Impact of informative censoring on the treatment effect estimate of disability worsening in multiple sclerosis clinical trialsKatherine Riester, Ludwig Kappos, Krzysztof Selmaj, et al.
Journal of Biopharmaceutical Statistics|March 16, 2012
A portfolio-based approach to optimize proof-of-concept clinical trialsCraig Mallinckrodt, Geert Molenberghs, Charles Persinger, et al.
Stem Cell Research & Therapy|January 20, 2021
MSC-NTF (NurOwn®) exosomes: a novel therapeutic modality in the mouse LPS-induced ARDS modelHaggai Kaspi, Jonathan Semo, Nathalie Abramov, et al.
Pharmaceutical Statistics|August 6, 2013
Use of historical control data for assessing treatment effects in clinical trialsKert Viele, Scott Berry, Beat Neuenschwander, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 16, 2022
Evaluation of neurotrophic factor secreting mesenchymal stem cells in progressive multiple sclerosisJeffrey A Cohen, Fred D Lublin, Christoper Lock, et al.
The American Journal of Psychiatry|May 2, 2006
Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosisThomas H McGlashan, Robert B Zipursky, Diana Perkins, et al.
Pageof 2